Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has provided an update.
Proteomics International Laboratories Ltd has received a $500,000 grant from the Western Australian Government to support the commercialization of PromarkerEndo, a pioneering blood test for diagnosing endometriosis. This funding will aid in regulatory, marketing, and partnership efforts, addressing the global health challenge of endometriosis, which affects one in nine women. The test offers a non-invasive alternative to current diagnostic methods, potentially transforming women’s healthcare by reducing the average seven-year diagnosis time, and is expected to launch in Australia in the second half of 2025.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, based in Perth, Western Australia, is a medical technology company specializing in precision diagnostics and bio-analytical services. The company focuses on proteomics, the large-scale study of proteins, and aims to enhance healthcare through innovative diagnostic tools.
Average Trading Volume: 338,131
Technical Sentiment Signal: Sell
Current Market Cap: A$53.2M
For a thorough assessment of PIQ stock, go to TipRanks’ Stock Analysis page.